“As part of our comprehensive and growing portfolio of single-cell multiomics solutions, the BD Rhapsody^™ ATAC-Seq Assay, together with other recently launched BD single-cell assays, enables our customers to more deeply understand even rare cells that are often the ‘key culprits’ in pathologies like cancer and infectious diseases,” said Steve Conly, worldwide president of Biosciences at BD. “By providing a complete portfolio of multiomics research tools, we are paving the way for scientists to tackle major challenges and develop innovative therapies leading to advancements in precision medicine. Our new single-cell multiomics assays, together with the BD Rhapsody^™ portfolio of reagents and bioinformatics tools, support our aim to provide a true end-to-end ecosystem of single-cell multiomics solutions for researchers – whether at academic research, biopharmaceutical or core lab facilities.”

Commercially available globally today, the BD Rhapsody^™ ATAC-Seq Assay, BD Rhapsody^™ TCR/BCR Next Multiomic Assay and Intracellular CITE-seq Assay using BD^® AbSeq Antibody-Oligos are designed to be used on the BD Rhapsody^™ Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell research. The BD single-cell multiomics portfolio is available for purchase from BD representatives, or in some regions, through our ecommerce portal. 
 

Learn more about BD Rhapsody^™ ATAC-Seq Assay